Cetera Advisor Networks’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$3.85M Buy
7,140
+452
+7% +$247K 0.02% 733
2023
Q4
$3.71M Sell
6,688
-387
-5% -$182K 0.02% 705
2023
Q3
$3.09M Sell
7,075
-76
-1% -$37.9K 0.02% 725
2023
Q2
$3.59M Sell
7,151
-177
-2% -$84.8K 0.02% 637
2023
Q1
$3.66M Buy
7,328
+176
+2% +$84.2K 0.03% 611
2022
Q4
$2.92M Buy
7,152
+6,506
+1,007% +$2.53M 0.02% 655
2022
Q3
$210K Sell
646
-96
-13% -$35.3K ﹤0.01% 1824
2022
Q2
$260K Buy
742
+18
+2% +$7.34K ﹤0.01% 1698
2022
Q1
$396K Sell
724
-105
-13% -$55.2K ﹤0.01% 1461
2021
Q4
$546K Buy
829
+50
+6% +$31.4K 0.01% 1232
2021
Q3
$484K Sell
779
-554
-42% -$372K 0.01% 1246
2021
Q2
$842K Buy
1,333
+381
+40% +$210K 0.01% 901
2021
Q1
$466K Buy
952
+111
+13% +$55.6K 0.01% 912
2020
Q4
$420K Buy
841
+200
+31% +$89.5K 0.01% 868
2020
Q3
$252K Buy
641
+141
+28% +$52.1K 0.01% 1032
2020
Q2
$165K Buy
+500
New +$145K ﹤0.01% 1224

Other funds holding IDXX

Cetera Advisor Networks's IDXX Position: Q1 2024 in Review

Cetera Advisor Networks increased its Idexx Laboratories (IDXX) stake by 6.8% in Q1 2024, buying an estimated $247K and bringing the position to 7,140 shares worth $3.85M. The position accounts for 0.02% of the portfolio, ranked #733.

Cetera Advisor Networks first reported a position in IDXX in Q2 2020 and has held it in 16 quarters since. 1,149 funds tracked by Wall St. Rank hold IDXX as of Q1 2024.

  • Cetera Advisor Networks held 7,140 shares of Idexx Laboratories worth $3.85M as of Q1 2024.
  • Cetera Advisor Networks bought 452 Idexx Laboratories shares in Q1 2024, an estimated $247K.
  • Idexx Laboratories made up 0.02% of Cetera Advisor Networks's portfolio in Q1 2024, its #733 holding.
  • Cetera Advisor Networks first reported a position in Idexx Laboratories in Q2 2020 and has held it in 16 quarters since.
  • 1,149 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2024.

Based on Cetera Advisor Networks's 13F filing for Q1 2024, filed 15 May 2024.